vs
BIOMERICA INC（BMRA）与Celldex Therapeutics, Inc.（CLDX）财务数据对比。点击上方公司名可切换其他公司
BIOMERICA INC的季度营收约是Celldex Therapeutics, Inc.的10.1倍（$1.2M vs $120.0K）。BIOMERICA INC净利率更高（-109.1% vs -67764.2%，领先67655.1%）。BIOMERICA INC同比增速更快（-26.0% vs -89.8%）。过去两年BIOMERICA INC的营收复合增速更高（9.1% vs -12.3%）
Biomerica Inc.是一家全球性医疗技术企业，研发、生产及销售诊断检测试剂盒与相关医疗产品，产品线覆盖胃肠疾病、传染病、食物不耐受检测及即时检测解决方案，服务全球多地的临床实验室、医疗机构及零售医疗客户。
Celldex Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性癌症和罕见免疫疾病的靶向免疫疗法，管线涵盖抗体药物偶联物、单克隆抗体等创新疗法，致力于满足大量未被满足的临床医疗需求。
BMRA vs CLDX — 直观对比
营收规模更大
BMRA
是对方的10.1倍
$120.0K
营收增速更快
BMRA
高出63.7%
-89.8%
净利率更高
BMRA
高出67655.1%
-67764.2%
两年增速更快
BMRA
近两年复合增速
-12.3%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $120.0K |
| 净利润 | $-1.3M | $-81.3M |
| 毛利率 | 4.2% | — |
| 营业利润率 | -113.5% | -72628.3% |
| 净利率 | -109.1% | -67764.2% |
| 营收同比 | -26.0% | -89.8% |
| 净利润同比 | -38.9% | -72.7% |
| 每股收益（稀释后） | $-0.45 | $-1.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRACLDX
| Q4 25 | $1.2M | $120.0K | ||
| Q3 25 | $1.4M | $0 | ||
| Q2 25 | $749.0K | $730.0K | ||
| Q1 25 | $1.1M | $695.0K | ||
| Q4 24 | $1.6M | $1.2M | ||
| Q3 24 | $1.8M | $3.2M | ||
| Q2 24 | $1.1M | $2.5M | ||
| Q1 24 | $1.0M | $156.0K |
净利润BMRACLDX
| Q4 25 | $-1.3M | $-81.3M | ||
| Q3 25 | $2.0K | $-67.0M | ||
| Q2 25 | $-1.5M | $-56.6M | ||
| Q1 25 | $-1.2M | $-53.8M | ||
| Q4 24 | $-950.0K | $-47.1M | ||
| Q3 24 | $-1.3M | $-42.1M | ||
| Q2 24 | $-1.4M | $-35.8M | ||
| Q1 24 | $-1.9M | $-32.8M |
毛利率BMRACLDX
| Q4 25 | 4.2% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | -33.0% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | 16.0% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -14.7% | — |
营业利润率BMRACLDX
| Q4 25 | -113.5% | -72628.3% | ||
| Q3 25 | -81.0% | — | ||
| Q2 25 | -209.1% | -8747.5% | ||
| Q1 25 | -108.1% | -9027.2% | ||
| Q4 24 | -60.7% | -4768.3% | ||
| Q3 24 | -75.7% | -1633.5% | ||
| Q2 24 | -136.6% | -1854.2% | ||
| Q1 24 | -196.7% | -26030.8% |
净利率BMRACLDX
| Q4 25 | -109.1% | -67764.2% | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | -206.1% | -7753.4% | ||
| Q1 25 | -103.9% | -7740.4% | ||
| Q4 24 | -58.1% | -4007.8% | ||
| Q3 24 | -72.8% | -1320.0% | ||
| Q2 24 | -127.1% | -1434.8% | ||
| Q1 24 | -188.6% | -21030.8% |
每股收益（稀释后）BMRACLDX
| Q4 25 | $-0.45 | $-1.23 | ||
| Q3 25 | $0.00 | $-1.01 | ||
| Q2 25 | $-0.99 | $-0.85 | ||
| Q1 25 | $-0.48 | $-0.81 | ||
| Q4 24 | $-0.06 | $-0.71 | ||
| Q3 24 | $-0.63 | $-0.64 | ||
| Q2 24 | $-2.57 | $-0.54 | ||
| Q1 24 | $-0.11 | $-0.56 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $518.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.4M | $527.2M |
| 总资产 | $6.0M | $583.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRACLDX
| Q4 25 | $2.5M | $518.6M | ||
| Q3 25 | $3.1M | $583.2M | ||
| Q2 25 | $3.1M | $630.3M | ||
| Q1 25 | $3.1M | $673.3M | ||
| Q4 24 | $2.4M | $725.3M | ||
| Q3 24 | $2.8M | $756.0M | ||
| Q2 24 | $4.2M | $802.3M | ||
| Q1 24 | $5.3M | $823.8M |
股东权益BMRACLDX
| Q4 25 | $4.4M | $527.2M | ||
| Q3 25 | $5.2M | $598.4M | ||
| Q2 25 | $4.1M | $655.4M | ||
| Q1 25 | $5.5M | $703.0M | ||
| Q4 24 | $5.1M | $747.0M | ||
| Q3 24 | $5.3M | $785.9M | ||
| Q2 24 | $6.6M | $813.7M | ||
| Q1 24 | $7.8M | $838.6M |
总资产BMRACLDX
| Q4 25 | $6.0M | $583.0M | ||
| Q3 25 | $6.9M | $648.4M | ||
| Q2 25 | $5.9M | $692.4M | ||
| Q1 25 | $7.4M | $739.5M | ||
| Q4 24 | $7.3M | $792.3M | ||
| Q3 24 | $7.9M | $823.2M | ||
| Q2 24 | $9.3M | $845.6M | ||
| Q1 24 | $10.3M | $868.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-991.0K | $-63.9M |
| 自由现金流经营现金流 - 资本支出 | — | $-65.2M |
| 自由现金流率自由现金流/营收 | — | -54350.8% |
| 资本支出强度资本支出/营收 | — | 1067.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-213.7M |
8季度趋势，按日历期对齐
经营现金流BMRACLDX
| Q4 25 | $-991.0K | $-63.9M | ||
| Q3 25 | $-268.0K | $-48.6M | ||
| Q2 25 | $-661.0K | $-44.0M | ||
| Q1 25 | $-1.0M | $-54.4M | ||
| Q4 24 | $-791.0K | $-32.5M | ||
| Q3 24 | $-1.3M | $-55.3M | ||
| Q2 24 | $-1.0M | $-29.3M | ||
| Q1 24 | $-1.8M | $-40.6M |
自由现金流BMRACLDX
| Q4 25 | — | $-65.2M | ||
| Q3 25 | — | $-49.1M | ||
| Q2 25 | — | $-44.7M | ||
| Q1 25 | — | $-54.6M | ||
| Q4 24 | — | $-33.2M | ||
| Q3 24 | — | $-55.9M | ||
| Q2 24 | $-1.1M | $-29.6M | ||
| Q1 24 | — | $-41.0M |
自由现金流率BMRACLDX
| Q4 25 | — | -54350.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -6127.8% | ||
| Q1 25 | — | -7861.4% | ||
| Q4 24 | — | -2828.3% | ||
| Q3 24 | — | -1751.2% | ||
| Q2 24 | -95.5% | -1185.0% | ||
| Q1 24 | — | -26270.5% |
资本支出强度BMRACLDX
| Q4 25 | — | 1067.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 99.7% | ||
| Q1 25 | — | 38.1% | ||
| Q4 24 | — | 64.3% | ||
| Q3 24 | — | 17.1% | ||
| Q2 24 | 2.1% | 11.0% | ||
| Q1 24 | 0.0% | 220.5% |
现金转化率BMRACLDX
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
